In this episode, Tom Lehmann talks with Accenture’s Ross Wooddisse, Managing Director and Life Sciences R&D Lead in Europe, about the 2022 Life Sciences Technology Vision and what the Metaverse continuum means for Biopharma R&D. They discuss how science turns into medicine, a new generation of digital trial capabilities and the fundamental opportunity for the industry to move from disease management towards risk prediction and disease prevention.